Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
1,500+ Patients Served Each Year 30,000+ Total Pounds We Help Our Clients Lose Each Year* Health Improvements We surveyed the last 500 people who completed the program
Henan Chuangxin Biological Technology Co., Ltd
As described above, the STENO-2 trial demonstrated that intensive control of multiple risk factors, including not only glycaemic, BP and lipid management but also the use of antiplatelet therapy in primary prevention and treatment of albuminuria with blockers of the reninangiotensin system, reduces microvascular and macrovascular diabetes complications and potentially mortality risk [1, 2]
10.1016/j.neuropharm.2011.07.036 40
Insights from benchmarking can inform and lead to changes in subsequent analyses for the expanded questions of interest
US$ 21.20
US$ 21.29
US$ 29.00
US$ 21.55
US$ 23.58
